Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade
A Prospective, Controlled Study To Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade Compared to Traditional Electrosurgery
Sponsor: Medtronic Surgical Technologies
A observational or N/A phase clinical study on Breast Cancer, this trial is completed. The trial is conducted by Medtronic Surgical Technologies and has accumulated 11 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Aug 2019 — Nov 2020 [monthly]
Completed
-
Jun 2018 — Aug 2019 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medtronic Surgical Technologies
- Sarah Blair, M.D.
For direct contact, visit the study record on ClinicalTrials.gov .